Research and Markets: PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022

Wed Mar 6, 2013 7:13am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130306:nBw065704a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/9llnsp/pharmapoint) has announced
the addition of GlobalData's new report "PharmaPoint: Epilepsy - Spain Drug
Forecast and Market Analysis to 2022" to their offering. 

GlobalData has released its new Country report, PharmaPoint: Epilepsy - Spain
Drug Forecast and Market Analysis to 2022. Epilepsy is a brain disorder
characterized by spontaneously occurring and recurrent seizures. The market is
heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure
reduction. The AED market is currently dominated by UCB's Keppra and
GlaxoSmithKline's Lamictal. Although both drugs have experienced significant
generic erosion, they form the mainstay of epilepsy treatment in the nine
markets and will continue to have significant market share during the forecast
period. 

Other key drugs include older generation AEDs such as Pfizer's Dilantin,
Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have
significant usage due to their longevity in the market. However, the AED
dominance landscape will continue to shift towards newer generation drugs
particularly following the recent market entry of GlaxoSmithKline's
Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of
action. 

The main drivers for growth in this market are the launch of new AEDs, the
continued uptake of recent AEDs, and the lower-than-average rate of generic
substitution in Spain compared with other countries, although this may change
during the forecast period due to government cost-cutting strategies. 

Scope 

- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape. 

- Detailed information on the key drugs in Spain including product description,
safety and efficacy profiles as well as a SWOT analysis. 

- Sales forecast for the top drugs in Spain from 2012-2022. 

- Analysis of the impact of key events as well the drivers and restraints
affecting Spain Epilesy market. 

For more information visit
http://www.researchandmarkets.com/research/9llnsp/pharmapoint

Source: GlobalData

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.